Thank you for your interest in enrolling in one of our studies.
New patients interested in participating in a clinical trial and in enrolling to possibly receive the newest, most advanced treatment for their vitreoretinal conditions, with the care and attention from our professional clinical trial staff.
New patients interested in enrolling a study, please click on the Enroll in this Study to send us an email. Include your name, the reason of your interest in this study and the office location you receive treatment. You will receive a reply from us within 48 - 72 hours.
The following studies are currently available for enrollment.
Study/Protocol Number: ANX007-GA-02 (Archer II)
Protocol Name: Archer II Treatment: IVT Indication: Geographic Atrophy
Title: A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Protocol Number: EYE-Res-102
Protocol name: Brunello
Treatment: IVT
Indication: Diabetic Macular Degeneration
Protocol Number: EYP-1901-301
Protocol Name: Lugano
Treatment: IVT Insert
Indication: Wet AMD
Protocol Number: OTX-TKI- 2023-AMD-303
Protocol Name: Sol-R
Treatment: Implant
Indication: Neovascular Age-Related macular Degeneration
Protocol Number: R3918-AMD-2326
Protocol Name: Sienna
Treatment: Subcutaneous Injection
Indication: Geographic Atrophy Secondary to Age-Related Macular Degeneration
Protocol Number: RGX-314-3101
Protocol Name: Ascent
Treatment: Gene Therapy
Indicaton: nAMD
Protocol Number: SPIAM-301
Protocol Name: ReNew
Treatment: Subcutaneous Injections Indication: Dry AMD
Norse Eight Wet AMD treatment naïve
Aviceda GA secondary to AMD
QUASAR - Retinal Vein Occlusions
ASCENT - Wet Macular Degeneration
ELEVATUM - Diabetic Macular Edema
SHANGHAI HENLIUS for Wet Age-Related Macular Degeneration
New Day is for Diabetic Macula EDEMA
Pulsar WET MACULAR DEGENERATION
Phase 2/3 double masked, Randomized, stage 2 Multicenter study of the Efficacy and Safety of OCS-01- Eye. Drops in Subjects with Diabetic Macular Edema
A Phase 3, Multicenter, Randomized, Parallel-Group, Double-Masked, 2-Arm, Sham Controlled study of the Efficacy, safety, and tolerability of ANX007 Administered by Intravitreal Injection in patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
A multicentre, randomized, sham-controlled, double masked, 72 week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy
A Phase 2, Double-masked, Randomized, Sham-controlled, Multiple-dose Study of the Efficacy and Safety of Intravitreal KUS121 in the Treatment of Non-Arteritic Central Retinal Artery Occlusion (CRAO) – GION-
A PHASE Ib, multicenter, randomized, double masked, active comparator-controlled study to investigate the biological activity, safety, tolerability, pharmacokinetics and pharmacodynamics of RO7200394 in participants with macular edema secondary to central retinal vein occlusion.
A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening.
Home OCT-Guided Treatment versus Treat and Extend for the Management of Neovascular AMD (Protocol AO)
Norse Eight Wet AMD treatment naïve
Pulsar WET MACULAR DEGENERATION
SHANGHAI HENLIUS FOR WET AMD
DRCR- Protocol AM- Epiretinal Membranes
Genentech, Inc – Magic ML43601- NPDR
ONL Therapeutics, Inc. (Retinal Detachment)
DRCR-Protocol AJ- Macula Hole
For more information about clinical trials or if you should have any questions, please feel free to contact us.
Clermont
Daytona Beach
Fernandina Beach
Fleming Island
Kissimmee
Jacksonville Oak Street
Jacksonville Perimeter Park
Lady Lake
Lake City
Lake Mary
Mount Dora
Orange City
Orlando
Palatka
Palm Coast
St. Augustine
Titusville
Wildwood
Mondays - Fridays: 8AM to 5PM
Saturdays - Sundays: Closed
In Case of Emergency: 911
contact@floridaretinainstitute.com